SPECIAL COVERAGE — Biologics
CDMO World > Europe, Pharmaceuticals > NEWS CAPSULES: Europe CDMO Pharmaceutical Manufacturing – August 2025

NEWS CAPSULES: Europe CDMO Pharmaceutical Manufacturing – August 2025

CDMOs across Europe are investing in pharmaceutical manufacturing—from pilot-scale and sterile fill-finish to organizational restructuring. These capsules highlight top moves from August 2025.

NEWS CAPSULES Europe Pharmaceutical Manufacturing

August 4, 2025

Pharmaceutical CDMOs in Europe are sharpening their focus on development-stage agility and sterile fill-finish capabilities while undergoing strategic reshaping to meet global demand. These Europe CDMO pharmaceutical manufacturing capsules summarize key moves from Recipharm and Lonza, including facility upgrades and divisional restructuring.

Capsule 1: Recipharm Launches Pilot-Scale Development Center in Germany

Sweden-based CDMO Recipharm announced the opening of a pilot-scale development facility in Bavaria to support oral solid dose development and scale-up. According to the company, the new site enables seamless progression from formulation to clinical supply under GMP. It includes capabilities for blending, granulation, compression, encapsulation, and coating.

Capsule 2: Recipharm Expands Blow-Fill-Seal (BFS) Sterile Platform

In a separate announcement, Recipharm said it had signed multiple new development contracts tied to its BFS platform. The company highlighted the ability to achieve over 90% API savings during formulation. The expansion is part of Recipharm’s broader strategy to support clinical-stage clients seeking cost-effective aseptic delivery systems.

Capsule 3: Lonza Reorganizes Under “One Lonza” CDMO Strategy

Lonza confirmed the restructuring of its business units under a “One Lonza” model aimed at streamlining its pharmaceutical CDMO offering. The reorg splits the company into three CDMO-focused divisions: Integrated Biologics, Advanced Synthesis (which includes small molecules), and Specialized Modalities. As part of the shift, Lonza is exiting its Capsules & Health Ingredients business. The company said this will sharpen its focus on core development and manufacturing activities.

Internal Link: Explore more Europe CDMO news at CDMOworld.com

Sourcing Note

This article summarizes announcements and insights from publicly available press releases and corporate updates. All companies mentioned are linked to their original sources. CDMOworld.com provides editorialized coverage for informational and industry awareness purposes.

Image placeholder

Lorem ipsum amet elit morbi dolor tortor. Vivamus eget mollis nostra ullam corper. Pharetra torquent auctor metus felis nibh velit. Natoque tellus semper taciti nostra. Semper pharetra montes habitant congue integer magnis.

User avatar placeholder
Written by CDMO

NEWS CAPSULES: China CDMO Pharmaceutical Manufacturing – August 2025

Pharmaceutical Cold Chain Logistics: Ensuring Drug Product Integrity and Compliance

Categories

Latest Articles

Subscribe to Newsletter

The Latest 

		[{"id":55295,"link":"https:\/\/cdmoworld.com\/single-use-systems-extractables-leachables-strategy-cdmo\/","name":"single-use-systems-extractables-leachables-strategy-cdmo","thumbnail":{"url":"https:\/\/cdmoworld.com\/wp-content\/uploads\/2026\/03\/Untitled-design-81.png","alt":"A group of scientists in lab coats and protective gear working together in a modern lab, performing research with test tubes, a microscope, and pipettes."},"title":"Single-Use Systems in Biologics Manufacturing: Extractables\/Leachables Strategy for CDMO","postMeta":[],"author":{"name":"CDMO World","link":"https:\/\/cdmoworld.com\/author\/raismrafiq\/"},"date":"Mar 6, 2026","dateGMT":"2026-03-06 12:24:58","modifiedDate":"2026-03-06 12:24:58","modifiedDateGMT":"2026-03-06 12:24:58","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/cdmoworld.com\/category\/qa\/\" rel=\"category tag\">Q&A<\/a>","space":"<a href=\"https:\/\/cdmoworld.com\/category\/qa\/\" rel=\"category tag\">Q&A<\/a>"},"taxonomies":{"post_tag":"<a href='https:\/\/cdmoworld.com\/tag\/biologics-manufacturing\/' rel='post_tag'>Biologics Manufacturing<\/a><a href='https:\/\/cdmoworld.com\/tag\/cdmo\/' rel='post_tag'>CDMO<\/a><a href='https:\/\/cdmoworld.com\/tag\/cgmp-compliance\/' rel='post_tag'>cGMP Compliance<\/a><a href='https:\/\/cdmoworld.com\/tag\/regulatory-compliance\/' rel='post_tag'>Regulatory Compliance<\/a><a href='https:\/\/cdmoworld.com\/tag\/tech-transfer\/' rel='post_tag'>Tech Transfer<\/a><a href='https:\/\/cdmoworld.com\/tag\/testing\/' rel='post_tag'>Testing<\/a>","content-type":"<a href='https:\/\/cdmoworld.com\/content-type\/articles\/' rel='content-type'>Articles<\/a>"},"readTime":{"min":8,"sec":12},"status":"publish","excerpt":"Transitioning to Single-Use Systems (SUS) offers speed but introduces chemical risks. This 2,500-word Q&A-style guide provides a comprehensive Extractables and Leachables Strategy for sponsors working with CDMOs. Discover expert tips on risk assessment, USP compliance, and analytical validation to ensure patient safety in biologics manufacturing."},{"id":55294,"link":"https:\/\/cdmoworld.com\/drug-substance-vs-drug-product-comparability-cdmo\/","name":"drug-substance-vs-drug-product-comparability-cdmo","thumbnail":{"url":"https:\/\/cdmoworld.com\/wp-content\/uploads\/2026\/03\/Untitled-design-80.png","alt":"A digital illustration contrasting drug substance and drug product, with vials of blue liquid on the left representing drug substance, and vials with capsules and tablets on the right representing drug products, all set in a futuristic lab environment."},"title":"Drug Substance vs Drug Product Comparability: How CDMO Changes Expand Your Study Scope","postMeta":[],"author":{"name":"CDMO World","link":"https:\/\/cdmoworld.com\/author\/raismrafiq\/"},"date":"Mar 6, 2026","dateGMT":"2026-03-06 12:09:04","modifiedDate":"2026-03-06 12:09:18","modifiedDateGMT":"2026-03-06 12:09:18","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/cdmoworld.com\/category\/tips\/\" rel=\"category tag\">Tips<\/a>","space":"<a href=\"https:\/\/cdmoworld.com\/category\/tips\/\" rel=\"category tag\">Tips<\/a>"},"taxonomies":{"post_tag":"<a href='https:\/\/cdmoworld.com\/tag\/biologics-manufacturing\/' rel='post_tag'>Biologics Manufacturing<\/a><a href='https:\/\/cdmoworld.com\/tag\/cdmo\/' rel='post_tag'>CDMO<\/a><a href='https:\/\/cdmoworld.com\/tag\/cgmp-compliance\/' rel='post_tag'>cGMP Compliance<\/a><a href='https:\/\/cdmoworld.com\/tag\/regulatory-compliance\/' rel='post_tag'>Regulatory Compliance<\/a><a href='https:\/\/cdmoworld.com\/tag\/tech-transfer\/' rel='post_tag'>Tech Transfer<\/a><a href='https:\/\/cdmoworld.com\/tag\/testing\/' rel='post_tag'>Testing<\/a>","content-type":"<a href='https:\/\/cdmoworld.com\/content-type\/articles\/' rel='content-type'>Articles<\/a>"},"readTime":{"min":7,"sec":11},"status":"publish","excerpt":"Navigating the nuances of Drug Substance vs Drug Product Comparability is vital when switching CDMOs. This 2,500-word guide provides expert tips on expanding your study scope. Learn how manufacturing changes impact analytical bridging and how to build a regulatory-compliant comparability plan that ensures safety for biologics."},{"id":55290,"link":"https:\/\/cdmoworld.com\/plasmid-dna-tech-transfer-cdmo-guide\/","name":"plasmid-dna-tech-transfer-cdmo-guide","thumbnail":{"url":"https:\/\/cdmoworld.com\/wp-content\/uploads\/2026\/03\/Untitled-design-79.png","alt":"A hand holding tweezers is shown cutting DNA strands, symbolizing genetic engineering and plasmid DNA technology transfer in a lab setting."},"title":"Plasmid DNA Tech Transfer to a CDMO: Process, Controls, and Release Testing","postMeta":[],"author":{"name":"CDMO World","link":"https:\/\/cdmoworld.com\/author\/raismrafiq\/"},"date":"Mar 6, 2026","dateGMT":"2026-03-06 11:49:25","modifiedDate":"2026-03-06 11:49:25","modifiedDateGMT":"2026-03-06 11:49:25","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/cdmoworld.com\/category\/sectors\/technology-transfer\/\" rel=\"category tag\">Technology Transfer<\/a>","space":"<a href=\"https:\/\/cdmoworld.com\/category\/sectors\/technology-transfer\/\" rel=\"category tag\">Technology Transfer<\/a>"},"taxonomies":{"post_tag":"<a href='https:\/\/cdmoworld.com\/tag\/biologics-manufacturing\/' rel='post_tag'>Biologics Manufacturing<\/a><a href='https:\/\/cdmoworld.com\/tag\/bioprocess-development\/' rel='post_tag'>Bioprocess Development<\/a><a href='https:\/\/cdmoworld.com\/tag\/cdmo\/' rel='post_tag'>CDMO<\/a><a href='https:\/\/cdmoworld.com\/tag\/cgmp-compliance\/' rel='post_tag'>cGMP Compliance<\/a><a href='https:\/\/cdmoworld.com\/tag\/regulatory-compliance\/' rel='post_tag'>Regulatory Compliance<\/a><a href='https:\/\/cdmoworld.com\/tag\/tech-transfer\/' rel='post_tag'>Tech Transfer<\/a>","content-type":"<a href='https:\/\/cdmoworld.com\/content-type\/articles\/' rel='content-type'>Articles<\/a>"},"readTime":{"min":8,"sec":36},"status":"publish","excerpt":"Plasmid DNA is the backbone of modern gene therapy and mRNA vaccine production. This 2,500-word technical guide explores the complexities of Plasmid DNA Tech Transfer to a CDMO. We analyze critical process parameters, analytical validation, and release testing requirements to ensure your scale-up meets global regulatory standards."},{"id":55285,"link":"https:\/\/cdmoworld.com\/adventitious-agent-testing-biologics-cdmo-strategy\/","name":"adventitious-agent-testing-biologics-cdmo-strategy","thumbnail":{"url":"https:\/\/cdmoworld.com\/wp-content\/uploads\/2026\/03\/Untitled-design-78.png","alt":"A researcher holding a test tube while examining cancerous cells under a microscope, illustrating biological research and testing in a lab environment."},"title":"Adventitious Agent Testing in Biologics: Building a CDMO Testing Strategy That Regulators Accept","postMeta":[],"author":{"name":"CDMO World","link":"https:\/\/cdmoworld.com\/author\/raismrafiq\/"},"date":"Mar 6, 2026","dateGMT":"2026-03-06 11:32:43","modifiedDate":"2026-03-06 12:11:12","modifiedDateGMT":"2026-03-06 12:11:12","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/cdmoworld.com\/category\/sectors\/quality-control\/\" rel=\"category tag\">Quality Control<\/a>","space":"<a href=\"https:\/\/cdmoworld.com\/category\/sectors\/quality-control\/\" rel=\"category tag\">Quality Control<\/a>"},"taxonomies":{"post_tag":"<a href='https:\/\/cdmoworld.com\/tag\/adventitious-agent-testing\/' rel='post_tag'>Adventitious Agent Testing<\/a><a href='https:\/\/cdmoworld.com\/tag\/biologics-manufacturing\/' rel='post_tag'>Biologics Manufacturing<\/a><a href='https:\/\/cdmoworld.com\/tag\/cdmo\/' rel='post_tag'>CDMO<\/a><a href='https:\/\/cdmoworld.com\/tag\/cgmp-compliance\/' rel='post_tag'>cGMP Compliance<\/a><a href='https:\/\/cdmoworld.com\/tag\/quality-control\/' rel='post_tag'>Quality Control<\/a><a href='https:\/\/cdmoworld.com\/tag\/regulatory-compliance\/' rel='post_tag'>Regulatory Compliance<\/a>","content-type":"<a href='https:\/\/cdmoworld.com\/content-type\/articles\/' rel='content-type'>Articles<\/a>"},"readTime":{"min":8,"sec":3},"status":"publish","excerpt":"Protecting biologics from viral, bacterial, and fungal contaminants is a regulatory mandate. This 2,500-word guide details Adventitious Agent Testing strategies at CDMOs. Explore in vitro and in vivo assays, Next-Generation Sequencing (NGS) trends, and how to structure your testing program to ensure safety and clinical success."},{"id":55283,"link":"https:\/\/cdmoworld.com\/rapid-mycoplasma-methods-biologics-qc-validation\/","name":"rapid-mycoplasma-methods-biologics-qc-validation","thumbnail":{"url":"https:\/\/cdmoworld.com\/wp-content\/uploads\/2026\/03\/Untitled-design-77.png","alt":"A lab technician in blue gloves adds a droplet to a Petri dish containing glowing mycoplasma colonies, while test tubes are prepared in the background in a modern laboratory setup."},"title":"Rapid Mycoplasma Methods in Biologics QC: When CDMOs Can Use Them and How to Validate","postMeta":[],"author":{"name":"CDMO World","link":"https:\/\/cdmoworld.com\/author\/raismrafiq\/"},"date":"Mar 6, 2026","dateGMT":"2026-03-06 11:12:20","modifiedDate":"2026-03-06 11:12:21","modifiedDateGMT":"2026-03-06 11:12:21","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/cdmoworld.com\/category\/features\/columns\/testing-matters\/\" rel=\"category tag\">Testing Matters<\/a>","space":"<a href=\"https:\/\/cdmoworld.com\/category\/features\/columns\/testing-matters\/\" rel=\"category tag\">Testing Matters<\/a>"},"taxonomies":{"post_tag":"<a href='https:\/\/cdmoworld.com\/tag\/biologics-manufacturing\/' rel='post_tag'>Biologics Manufacturing<\/a><a href='https:\/\/cdmoworld.com\/tag\/cdmo\/' rel='post_tag'>CDMO<\/a><a href='https:\/\/cdmoworld.com\/tag\/cgmp-compliance\/' rel='post_tag'>cGMP Compliance<\/a><a href='https:\/\/cdmoworld.com\/tag\/quality-control\/' rel='post_tag'>Quality Control<\/a><a href='https:\/\/cdmoworld.com\/tag\/regulatory-compliance\/' rel='post_tag'>Regulatory Compliance<\/a><a href='https:\/\/cdmoworld.com\/tag\/testing\/' rel='post_tag'>Testing<\/a>","content-type":"<a href='https:\/\/cdmoworld.com\/content-type\/articles\/' rel='content-type'>Articles<\/a>"},"readTime":{"min":7,"sec":52},"status":"publish","excerpt":"Traditional mycoplasma testing takes 28 days, delaying critical patient therapies. This 2,500-word guide explores Rapid Mycoplasma Methods, detailing when CDMOs can implement them and the rigorous validation steps required to satisfy global regulators. Learn how to accelerate your biologics QC without compromising safety or compliance."}]
Sponsor or AdvertiseMedia Kit
Latest Tips
Latest Q&A
CDMWorld Footer